Know Cancer

forgot password

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study

Phase 3
18 Years
Open (Enrolling)
Lung Cancer

Thank you

Trial Information

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study


- Compare the efficacy of polyglutamate paclitaxel (CT-2103) and carboplatin vs
paclitaxel and carboplatin, in terms of duration of overall survival, in patients with
stage IIIB or IV or recurrent non-small cell lung cancer who have a performance status
of 2.

- Compare the disease control (percentage of patients with no disease progression for at
least 12 weeks) and time to progression in patients treated with these regimens.

- Compare the response rate in patients with measurable disease treated with these

- Compare the improvement in lung cancer symptoms in patients treated with these

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
according to gender, disease stage (IV vs other), geographic location (US vs Western Europe
and Canada vs the rest of the world), and prior brain metastases (yes vs no). Patients are
randomized to 1 of 2 treatment arms.

- Arm I: Patients receive polyglutamate paclitaxel (CT-2103) IV over 10 minutes and
carboplatin IV over 30 minutes on day 1.

- Arm II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes
on day 1.

Treatment repeats in both arms every 21 days for 6 courses in the absence of disease
progression or unacceptable toxicity.

Patients are followed at 3 weeks and then every 8 weeks thereafter.

PROJECTED ACCRUAL: A total of 370 patients (185 per treatment arm) will be accrued for this
study within 13 months.

Inclusion Criteria


- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) meeting
1 of the following criteria:

- Locally advanced or recurrent disease previously treated with radiotherapy
and/or surgery

- Stage IIIB and not a candidate for combined modality therapy

- Stage IV

- No evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell

- Cytological diagnosis must be based on the following:

- No cellular diagnosis by sputum cytology alone

- Cytologic specimens obtained from brushings, washings, or needle aspiration of a
defined lesion or pleural effusion are acceptable

- Measurable or nonmeasurable disease

- Brain metastases allowed provided patient received prior standard antitumor therapy
for CNS metastases (e.g., whole brain radiotherapy, stereotactic radioablation, or
surgery) and the following conditions are met:

- Neurologic function stable for at least 2 weeks before study entry

- Off steroid therapy or on a tapering regimen

- Recovered from prior therapy



- 18 and over

Performance status

- ECOG 2

Life expectancy

- Not specified


- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3


- Bilirubin no greater than upper limit of normal (ULN)

- SGOT/SGPT no greater than 2.5 times ULN (5 times ULN if liver metastases present)

- Alkaline phosphatase no greater than 2.5 times ULN (except for laboratory
documentation that demonstrates bone origin)


- Creatinine no greater than 1.5 times ULN


- No unstable angina

- No myocardial infarction within the past 6 months

- Cardiac conduction abnormalities (e.g., bundle branch block or heart block) allowed
provided cardiac status has been stable for at least 6 months prior to study entry


- See Disease Characteristics

- No neuropathy greater than grade 1

- No evidence of unstable neurological symptoms within the past 4 weeks (2 weeks for
neurological symptoms due to brain metastases)


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No intolerance to excipients of polyglutamate paclitaxel (e.g., poly-L-glutamic acid,
poloxamer 188, dibasic sodium phosphate, or monobasic sodium hydroxide)

- No clinically significant active infection

- No other concurrent primary malignancy except carcinoma in situ or nonmelanoma skin

- No other unstable medical conditions

- No circumstance that would preclude study completion or follow-up


Biologic therapy

- No prior systemic biologic agent for lung cancer


- See Disease Characteristics

- No prior systemic therapy for lung cancer including radiosensitizing agents

Endocrine therapy

- See Disease Characteristics


- See Disease Characteristics

- No concurrent radiotherapy


- See Disease Characteristics

- Recovered from prior major surgery


- More than 12 weeks since prior participation in any research study or treatment with
investigational drugs

- Recovered from prior investigational therapy or stable for 4 weeks before study

- No other concurrent investigational drugs

- No other concurrent systemic antitumor therapy

- No concurrent amifostine

- Concurrent bisphosphonates allowed

Type of Study:


Study Design:

Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Melinda Bomar

Investigator Role:

Study Chair

Investigator Affiliation:

PPD, Incorporated


United States: Federal Government

Study ID:




Start Date:

January 2003

Completion Date:

Related Keywords:

  • Lung Cancer
  • recurrent non-small cell lung cancer
  • stage IIIB non-small cell lung cancer
  • stage IV non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



University of Texas - MD Anderson Cancer Center Houston, Texas  77030-4009
Columbia Comprehensive Cancer Care Clinic Columbia, Missouri  65201
Hattiesburg Clinic, P.A. Hattiesburg, Mississippi  39401
Cancer Therapy and Research Center San Antonio, Texas  78229
Silver Cross Hospital Joliet, Illinois  60432
Arizona Clinical Research Center Tucson, Arizona  85712
Hematology Oncology, P.C. Stamford, Connecticut  06902
Bond Clinic Rolla, Missouri  65401
California Hematology/Oncology Medical Group Torrance, California  90505
Flint, Michigan  48532
Santee Hematology Oncology Sumter, South Carolina  29150
Clinical Research Consultants, Inc Hoover, Alabama  35216
Family Cancer Center Collierville, Tennessee  38017
Summit Medical Group, P.A. Summit, New Jersey  07901
Rainier Oncology Puyallup, Washington  98372
Hematology Oncology Associates of theTreasure Coast - Port St. Lucie Port Saint Lucie, Florida  34952
Charleston Cancer Center Charleston, South Carolina  29406
Synergy Hematology/Oncology Medical Associates Encino, California  91316
Gross Point Medical Center Skokie, Illinois  60077
Kentucky Cancer Clinic Pikeville, Kentucky  41501
Las Vegas Cancer Center Las Vegas, Nevada  89102
Gabrail Cancer Center - Canton Office Canton, Ohio  44718
Virginia Oncology Care P.C. Richlands, Virginia  24641
Hematology and Oncology Associates of Alabama Birmingham, Alabama  35243
Holy Cross Providence Cancer Center Mission Hills, California  91345
Clinical Trials and Research Associates, Incorporated Montebello, California  90640
New Hope Cancer Centers Hudson, Florida  34667
Omni Healthcare, PA Melbourne, Florida  32901
MetCare Oncology Ormond Beach, Florida  32174
Northwest Georgia Oncology Centers, P.C. Marietta, Georgia  30060
Georgia Cancer Specialists - Tucker Tucker, Georgia  30084
Oklahoma Oncology, Inc. - St. John Campus Tulsa, Oklahoma  74104
Clarksville Regional Hematology/Oncology Group Clarksville, Tennessee  37043
Highline Medical Oncology Burien, Washington  98166